Sociedad
Española de
Nefrología

Original article

Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease

Ezequiel Ridruejo [a,b,c], Rebeca Garcia-Agudo [d], Manuel Mendizabal [b,c], Sami Aoufi-Rabih [e], Vivek Dixit [f], Marcelo Silva [b,c], Fabrizio Fabrizi [g,*]

[a] Hepatology Section, Department of Medicine, Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno "CEMIC", Ciudad Autonoma de Buenos Aires, Argentina
[b] Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Provincia de Buenos Aires, Argentina
[c] Latin American Liver Research, Educational and Awareness Network (LALREAN), Pilar, Provincia de Buenos Aires, Argentina
[d] Nephrology Department, La Mancha-Centro Hospital, Alcázar de San Juan, Ciudad Real, Spain
[e] Gastroenterology and Hepatology Department, La Mancha-Centro Hospital, Alcázar de San Juan, Ciudad Real, Spain
[f] Division of Gastroenterology, Hepatology and Parenteral Nutrition, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
[g] Division of Nephrology, Maggiore Hospital and IRCCS Foundation, Milano, Italy

ABSTRACT

Background and aims: The advent of direct-acting antiviral agents promises to change the management of hepatitis C virus infection (HCV) in patients with chronic kidney disease (CKD), a patient group in which the treatment of hepatitis C was historically challenging. We investigated the safety and efficacy of all-oral, interferon-free direct-acting antiviral agents for the treatment of hepatitis C in a 'real-world' cohort of patients with CKD.

Methods: We performed an observational single-arm multi-centre study in a large ($n = 198$) cohort of patients with stage 1–3 CKD who underwent antiviral therapy with DAAs for the treatment of HCV. The primary end-point was sustained virologic response (serum HCV RNA <15 IU/mL, 12 weeks after treatment ended) (SVR12). We collected data on on-treatment adverse events (AEs), severe AEs, and laboratory abnormalities.

Results: The average baseline eGFR (CKD-EPI equation) was 70.06 ± 20.1 mL/min/1.72 m^2; the most common genotype was HCV 1b ($n = 93$, 51%). Advanced liver scarring was found in 58 (46%) patients by transient elastography. Five regimens were adopted: elbasvir/grazoprevir ($n = 5$), glecaprevir/pibrentasvir ($n = 4$), ritonavir-boosted paritaprevir/ombitasvir/dasabuvir (PrOD) regimen ($n = 40$), simeprevir ± daclatasvir ($n = 2$), and sofosbuvir-based combinations ($n = 147$). The SVR12 rate was 95.4% (95% CI, 93.8%; 96.8%). There were nine virological failures – eight being relapsers. Adverse events occurred in 30% (51/168) of patients, and were managed clinically without discontinuation of therapy or hospitalization. One of the most

* Corresponding author.
E-mail address: fabrizi@policlinico.mi.it (F. Fabrizi).

common AEs was anaemia ($n = 12$), which required discontinuation or dose reduction of ribavirin in some cases ($n = 6$); deterioration of kidney function occurred in three (1.7%).

Conclusions: All-oral, interferon-free therapy with DAAs for chronic HCV in mild-to-moderate CKD was effective and well-tolerated in a 'real–world' clinical setting. Studies are in progress to address whether sustained viral response translates into better survival in this population.

Eficacia y seguridad de los antivíricos de acción directa para el VHC en la nefropatía crónica de leve a moderada

R E S U M E N

Palabras clave:
Efectos adversos
Antivíricos
Hepatitis C
Insuficiencia renal
Respuesta virológica sostenida

Antecedentes y objetivos: La aparición de los antivíricos de acción directa (AAD) promete cambiar el tratamiento de la infección por el virus de la hepatitis C (VHC) en los pacientes con nefropatía crónica (NC), un grupo de pacientes en el que el tratamiento de la hepatitis C siempre supuso una dificultad. Se investiga la seguridad y la eficacia de los antivíricos de acción directa, sin interferones orales, en todos los casos para el tratamiento de la hepatitis C en una cohorte en condiciones reales de pacientes con NC.

Métodos: Se llevó a cabo un estudio multicéntrico, de un solo grupo y observacional en una cohorte amplia ($n = 198$) de pacientes con NC en estadio 1-3 a los que se administró tratamiento antivírico con AAD para el VHC. El criterio principal de valoración fue la respuesta virológica sostenida (ARN sérico del VHC < 15 UI/ml, 12 semanas después de la finalización del tratamiento) (RVS12). Se recogieron los datos sobre acontecimientos adversos (AA) surgidos durante el tratamiento, AA graves y anomalías analíticas.

Resultados: La FGe inicial media (ecuación de CKD-EPI) fue de $70,06 \pm 20,1$ ml/min/1,72 m^2; el genotipo más frecuente fue VHC 1b ($n = 93$; 51%). Se observó cicatrización hepática avanzada en 58 (46%) pacientes mediante elastografía transitoria. Se adoptaron 5 pautas: elbasvir/grazoprevir ($n = 5$), glecaprevir/pibrentasvir ($n = 4$), pauta de paritaprevir/ombitasvir/dasabuvir (PrOD) potenciada con ritonavir ($n = 40$), simeprevir ± daclatasvir ($n = 2$) y combinaciones basadas en sofosbuvir ($n = 147$). La tasa de RVS12 fue del 95,4% (IC del 95%: 93,8; 96,8%). Hubo 9 fracasos virológicos, 8 de ellos recidivantes. Se produjeron acontecimientos adversos en el 30% (51/168) de los pacientes, que se trataron clínicamente sin suspensión del tratamiento ni hospitalización. Uno de los AA más frecuentes fue la anemia ($n = 12$), que precisó la suspensión o la reducción de la dosis de ribavirina en algunos casos ($n = 6$); se produjo deterioro de la función renal en 3 casos (1,7%).

Conclusiones: El tratamiento sin interferón oral en todos los casos con AAD para el VHC crónico en la NC de leve a moderada fue eficaz y bien tolerado en un contexto de la práctica clínica real. Hay estudios en curso para abordar si la respuesta viral sostenida se traduce en una mejor supervivencia en esta población.

Introduction

Hepatitis C virus (HCV) infection is a common infectious disease with a prevalence of 71 million HCV-infected individuals all over the world.[1] Evidence has accumulated over the last two decades reporting a variety of extra-hepatic diseases induced by HCV; HCV-negative individuals have lower non-liver-related mortality compared to those who are chronically infected with HCV.[2] The extra-hepatic activity of HCV is added to its action on the liver that manifest itself with cirrhosis and

hepatocellular carcinoma, the main complications of chronic liver disease.

The kidneys are an important target of chronic HCV, the relationship between HCV and the kidneys has bidirectional nature and is complex. On one side, kidney failure supports the diffusion of HCV (mostly via dialysis environment) particularly in the developing world where the compliance to the infection control procedures against HCV spread within dialysis units is frequently missing. On the other, HCV increases the risk of renal impairment. In addition to conventional risk factors for chronic kidney disease (ageing, metabolic syndrome,

arterial hypertension, and diabetes) HCV infection may be an additional risk factor.

The detrimental role of chronic HCV on the incidence and progression of chronic kidney disease in the general population has been recently emphasized. A meta-analysis of observational studies (n = 40 studies, n = 4,072,867 unique patients) demonstrated an association between positive anti-HCV serologic status and increased incidence of CKD.[3] We found a significant association between positive anti-HCV serologic status and increased frequency of proteinuria, adjusted risk of proteinuria associated with HCV across the surveys, 1.633 (95% CI, 1.29; 2.05). Test for homogeneity of the adjusted risk of proteinuria across the ten studies gave a Q value of 37.47 (I^2 = 75.9%) (P = 0.0001). That is, the homogeneity assumption was rejected.[3]

The advent of the direct-acting antiviral agents (DAAs) is dramatically changing the management of HCV in the general populations including the 'difficult-to-treat' groups such as CKD patients. According to the guidelines provided by the AASLD/IDSA, two regimens based on DAAs have been suggested for HCV in advanced CKD.[4] On the contrary, various combinations have been recommended in patients with mild-to-moderate renal impairment.[4,5] However, the data in the medical literature regarding the use of DAAs in patients with stage 1–3 chronic kidney disease are extremely limited.[6–9]

The aim of this study is to evaluate efficacy and safety of therapy with DAAs for HCV in patients with mild-to-moderate chronic kidney disease in a 'real-life' clinical practice. Various regimens based on DAAs have been retrospectively reviewed including the most recent combinations.

Material and methods

Study design and eligibility of patients

This was a retrospective analysis of patients with stage 1–3 CKD (followed at some units of Europe and America) and chronic HCV who received antiviral therapy with DAAs. We included adult patients aged 18 years and older diagnosed with chronic HCV infection, who took at least one dose of a DAA therapy between April 2013 and August 2018. Patients were included irrespective of their liver fibrosis stage, genotype, or prior HCV treatment status.

Pre-treatment stage of liver fibrosis was evaluated by transient elastography (Fibroscan®, Echosens, Paris, France). Liver fibrosis stage (F1-F4) was derived from the liver stiffness values in kPa obtained by transient elastography on the grounds of the indications provided by the manufacturer.

Antiviral regimen

DAA regimens were prescribed at the discretion of the treating physician depending on the genotype, baseline HCV viraemia, presence of liver fibrosis/cirrhosis, and prior treatment experience. Various antiviral regimens were administered: EBR/GZR (elbasvir was prescribed at 50 mg administered orally once daily in co-formulation with grazoprevir 100 mg administered orally once daily fixed dose); PrOD regimen (ritonavir-boosted paritaprevir/ombitasvir/dasabuvir) ± ribavirin, administered

at standard doses (ombitasvir, 25 mg once daily/paritaprevir, 150 mg once daily/ritonavir, 100 mg once daily/dasabuvir, 250 mg twice daily); GP (glecaprevir was prescribed at 100 mg administered orally in co-formulation with pibrentasvir, 40 mg, three times daily for 12 weeks). Sofosbuvir-based regimens were: LDV/SOF ± ribavirin (ledipasvir was prescribed at 90 mg administered orally once daily in co-formulation with sofosbuvir 400 mg [fixed dose]); sofosbuvir and ribavirin (sofosbuvir was prescribed at 400 mg administered orally once daily and weight-adjusted ribavirin doses orally once daily); SOF/DCV ± ribavirin (daclatasvir was prescribed at 60 mg administered orally once daily in co-formulation with sofosbuvir 400 mg); SOF/VEL ± ribavirin (velpatasvir was prescribed at 100 mg administered orally once daily in co-formulation with sofosbuvir at 400 mg orally once daily); sofosbuvir (400 mg) and simeprevir (150 mg) (SOF/SIM) were administered in a single tablet fixed-dose combination once daily. A minority of patients received sofosbuvir (400 mg once daily orally) plus daclatasvir (60 mg once daily orally) ± ribavirin.

Sustained virological response was defined according to AASLD/IDSA recommendations as an undetectable HCV RNA 12 weeks after the end of antiviral therapy.[4] Duration of treatment ranged from 12 to 24 weeks depending on the treating physician, in accordance with product label. RBV was never administered in a syrup and the minimum prescribed dose was 200 mg a day; the dose of RBV dose was prescribed from the treating physician based on body weight and renal function.

Laboratory assessments

Serum HCV RNA was measured using the quantitative COBAS AMPLICOR HCV (Roche) Monitor Assay (limit of detection, 15 log IU/mL). HCV genotyping was determined at baseline by the SIEMENS Versant HCV Genotype 2.0 Assay (LiPA) (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA). The eGFR was assessed by CKD-EPI Equation in all patients. All measurements of AST, ALT and gamma-GT were made by spectrophotometric method. The upper limits in the serum AST and ALT assays were 40 and 40 IU/L respectively; the upper limits in the serum gamma-GT were 55 IU/L. eGFR was estimated using the CKD Epidemiology Collaboration equation.[10]

Safety evaluation

The patients were monitored on a regular basis for treatment efficacy and side-effects. The patients' visits were scheduled as follows: treatment initiation, treatment weeks 4,8, 12, and 12 weeks post-treatment. Each visit consisted of a query on medical history and side effects, check of concomitant medication, physical examination, laboratory analyses, and drug delivery. Laboratory analyses included blood chemistry, blood count, prothrombin time, and HCV RNA. The structure of recordings of adverse events (AEs) was as follows: any AE or serious adverse event (SAE), which included any event requiring hospitalization, life-threatening event, or death; the relationship with the administered medication was also assessed. The study was reported according to the STROBE

initiative.[11] The 22 items regarding the current manuscript are reported in the Supplemental File n. 1.

Statistical analysis

Data are presented as means and standard deviations or medians with respective ranges, as appropriate. Serum aminotransferase and gamma-glutamyl transpeptidase were logarithmically transformed (natural logarithm) to obtain normal distribution and then were subjected to statistical tests. For all comparisons, a two-sided P value <0.05 was considered to indicate statistical significance throughout the study. All analyses were made with Stata, version 9.0 (StataCorp, College Station, TX).

Ethical standard

All procedures during the study were conducted in accordance with the International Conference on Harmonization guidelines, and ethical principles that have their origin in the Declaration of Helsinki. The requirement for informed consent was waived because of the retrospective design of the study and use of data from which the patients' identification information had been removed.

Results

Baseline patient demographics

The baseline demographic and clinical characteristics of patients included in the study group are shown in Tables 1 and 2. The majority of patients were Caucasian

Table 1 – Demographic and clinical patients' characteristics at baseline: patients with stage 1–3 chronic kidney disease.

Characteristics	Patients ($n = 198$)
Age, years	63.5 ± 10.9
Males, n	133 (67.1%)
Caucasian, n	192 (96.9%)
Liver transplant recipients, n	47 (23.7%)
HCV genotype, n = 182	
1a	28
1b	93
1	2
2	30
3	19
4	10
Arterial hypertension, n	90 (45.7%)
HBV co-infection, n	2 (1.0%)
Liver fibrosis, n = 126	
F1	27
F2	16
F3	25
F4	58
Diabetes mellitus, n	57 (28.9%)

HBV, Hepatitis B virus infection; HCV, hepatitis C virus infection.

Table 2 – Clinical and biochemical patients' characteristics at baseline: patients with stage 1–3 chronic kidney disease.

Characteristics	Patients ($n = 198$)
HIV co-infection, n	6 (3.0%)
Treatment-experienced ($n = 132$)	55 (41.9%)
Serum creatinine, mg/dL	1.13 ± 0.3
eGFR (mL/min/1.73 m^2)	70.06 ± 20.1
INR ($n = 79$)	1.20 ± 1.12
Haemoglobin, g/dL ($n = 103$)	13.7 ± 1.78
Albumin, g/dL ($n = 102$)	3.92 ± 0.56
Total bilirubin, mg/dL ($n = 101$)	1.06 ± 1.37
Platelet, 109 L^{-1} ($n = 105$)	181.8 ± 87.1
HCV RNA, logn IU/mL	13.51 ± 2.03

eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; HCV RNA, hepatitis C virus ribonucleic acid; INR, international normalized ratio.

(96.5%) and male (70%). As listed in Table 1 the study group included patients with functioning liver transplant and no significant differences occurred between LT and non-LT recipients regarding baseline parameters (data shown). Liver fibrosis was assessed by transient elastography in a subset ($n = 126$) of patients. Stage 3 CKD was found in 66 (33.3%) patients. The most common genotype was HCV 1b (50.0%), and 55 (30%) patients were treatment-experienced. Antiviral therapy was conducted with various ($n = 5$) regimens of DAAs: EBR/GZR ($n = 5$), GP ($n = 4$), PrOD regimen ± RBV ($n = 40$), simeprevir ± daclatasvir ± RBV ($n = 2$), and sofosbuvir-based combinations ($n = 147$). Sofosbuvir-based combinations included sofosbuvir ± RBV, SOF/DCV ± RBV, SOF/VEL ± RBV, LDV/SOF ± RBV, and SOF/SIM (Table 3).

Efficacy outcomes

All patients completed treatment course and subsequent follow-up. The SVR12 rate was 95.4% (189/198) (95% CI, 93.8%; 96.8%), according to an ITT analysis. There were nine virological failures; one and eight were non-responders and relapsers, respectively. The genotypes of virological failures were: 1a ($n = 1$), 1b ($n = 5$) and 2 ($n = 3$), respectively. The combinations of DAAs in virological failures were: elbasvir/grazoprevir ($n = 1$), PrOD ($n = 1$), simeprevir/daclatasvir ($n = 1$), sofosbusvir ± RBV ($n = 2$), sofosbuvir/daclatasvir ± RBV ($n = 3$), and sofosbuvir/simeprevir ($n = 1$). No difference occurred regarding clinical and biochemical characteristics between responder and non-responder patients at baseline – all the comparisons reported in Table 4 were not significant. There was no significant difference between LT recipients and those without liver grafts with regard to the SVR12 rate, 24.3% (46/189) vs. 75% (143/189), P = 0.69.

The dynamics of liver enzymes (aminotransferase and gamma-glutamyl transpeptidase) during and after antiviral therapy with DAAs were observed in a subgroup of patients ($n = 94$ patients). AST, ALT and GGT lowered significantly after therapy with DAAs and over the follow-up (Table 5).

Table 3 – Combinations of direct-acting antiviral agents and treatments in patients with stage 1–3 chronic kidney disease (n = 182 patients).

HCV genotype	DAAs combination	Patients, n
1	Elbasvir/Grazoprevir	4
	PrOD regimen ± RBV	37
	Simeprevir/Daclatasvir ± RBV	2
	Sofosbuvir/RBV	8
	Sofosbuvir/Daclatasvir ± RBV	37
	Sofosbuvir/Velpatasvir ± RBV	2
	Ledipasvir/Sofosbuvir ± RBV	30
	Sofosbuvir/Simeprevir	2
	Glecaprevir/Pibrentasvir	1
2	Glecaprevir/Pibrentasvir	2
	Sofosbuvir/Daclatasvir ± RBV	20
	Sosfosbuvir/RBV	7
	Sofosbuvir/Velpatasvir ± RBV	1
3	Sofosbuvir/Daclatasvir ± RBV	13
	Ledipasvir/Sofosbuvir ± RBV	1
	Sofosbuvir/Ribavirin	4
	Sofosbuvir/Velpatasvir ± RBV	1
4	PrOD regimen ± RBV	1
	Sofosbuvir/Daclatavsir ± RBV	1
	Ledipasvir/Sofosbuvir ± RBV	5
	Sofosbuvir/Ribavirin	2
	Sofosbuvir/Velpatasvir ± RBV	1

DAAs, direct-acting antiviral agents; PrOD, ritonavir-boosted paritaprevir/ombitasvir/dasabuvir; RBV, ribavirin.

Table 4 – Demographic and clinical patients' characteristics: responders vs. non-responders.

Characteristics	Responders to DAAs (n = 189)	Not Responders (n = 9)
Age, years	63.3 ± 10.9	67.5 ± 10.4
Males	127 (67.1%)	6 (67%)
Caucasian	183 (96.8%)	9 (100%)
Liver transplant recipients	46 (24.3%)	1 (11%)
HCV genotype 1b (n = 182)	88 (50.8%)	5 (55.5%)
HCV RNA	2,814,411 ± 4908	6,383,000 ± 14,515
Arterial hypertension	89 (47.0%)	1 (11.1%)
HBV co-infection	2 (1.0%)	0
HIV co-infection	6 (3.1%)	0
Liver fibrosis, n = 126 (F4 stage)	55 (47%)	3 (33%)
Diabetes mellitus	52 (27.5%)	5 (20%)
Treatment-experienced (n = 55)	52 (27.5%)	3 (33.3%)
Serum creatinine, mg/dL	1.11 ± 0.3	1.06 ± 0.21
HCV RNA, logn IU/mL	13.45 ± 2.05	14.4 ± 1.34

DAAs, direct-acting antiviral agents; HBV, hepatitis B virus infection; HCV RNA, hepatitis C virus ribonucleic acid; HIV, human immunodeficiency virus; INR, international normalized ratio.

Safety outcomes

All patients completed antiviral therapy and subsequent follow-up (drop-out rate, 0%). Adverse events were recorded in a subset of patients (n = 158); 58 individuals had at least one AE.

Table 5 – Liver biochemical tests at baseline, after antiviral therapy and over the follow-up with DAAs: patients with stage 1–3 chronic kidney disease (n = 94 patients).

	Baseline	EOT	W12
AST, IU/L	46.9 ± 1.9[*]	24.1 ± 1.7	24.2 ± 1.5
ALT, IU/L	45.5 ± 2.2[**]	21.2 ± 2.1	19.3 ± 4.5
GGT, IU/L	85.1 ± 14.2[***]	37.1 ± 11.2	36.5 ± 10.5

[*] AST, baseline vs. EOT (P = 0.001) and baseline vs. W12 (P = 0.001).
[**] ALT, baseline vs. EOT (P = 0.001) and baseline vs. W12 (P = 0.001).
[***] GGT, baseline vs. EOT (P = 0.001) and baseline vs. W12 (P = 0.001).
AST, aspartate aminotransferase, ALT, alanine aminotransferase; EOT, end of treatment; GGT, gamma glutamyl transpeptidase; W12, week 12.

Table 6 – AEs experienced during treatment with DAAs (information on AEs was not available in 30 patients).

Adverse events (n = 168 patients)	
Abdominal discomfort	1
Anaemia	9
Arthralgias	1
Diarrhoea	1
Dizziness	1
Oedema	1
Fatigue	13
Headache	9
Insomnia	2
Icthing	4
Nausea	1
Rash	5
Worsening of kidney function	3

AEs, adverse events.

Most AEs events were mild, and were managed clinically without discontinuation of therapy. The most common AEs were fatigue (n = 13), anaemia (n = 9), and headache (n = 9), respectively. Severe anaemia requiring reduction or discontinuation of ribavirin occurred in some cases (n = 6) (Table 6).

Three (1.7%) patients showed irreversible worsening of kidney function during antiviral therapy with DAAs, the increase in serum creatinine was less than 30% of baseline levels (stage 3 CKD in all at baseline). These patients received SOF-based treatments, SOF/DCV (n = 2) and LDV/SOF (n = 1).

Hospitalizations were not necessary during antiviral therapy and 12-week follow-up. No documented episodes of graft rejection occurred among liver transplant recipients on DAAs (n = 47). We found no significant differences regarding several biochemical parameters between baseline and EOT values (Table 6). The average values of serum albumin and eGFR increased significantly after completing antiviral therapy with DAAs (Table 7), this occurred regardless of whether the patient was a LT recipient or not (data not shown).

Discussion

Most RCTs of DAAs in the general population included patients with intact kidneys and the majority of studies with CKD patients (such as C-SURFER, RUBY-1, and EXPEDITION-4) involved individuals with advanced CKD.[12–14] The aim of this

Table 7 – Clinical and biochemical patients' characteristics (patients with stage 1–3 chronic kidney disease): baseline vs. end-of-treatment.

Characteristics	Baseline	EOT
Serum creatinine, mg/dL (n = 167)	1.12 ± 0.3	1.12 ± 0.34
eGFR (mL/min/1.73 m²) (n = 80)	71.1 ± 14.5	73.9 ± 17.8[*]
INR (n = 54)	1.05 ± 1.12	1.04 ± 0.13
Haemoglobin, g/dL (n = 83)	13.7 ± 1.84	13.7 ± 2.04
Albumin, g/dL (n = 79)	3.99 ± 0.37	4.23 ± 0.4[**]
Total bilirubin, mg/dL (n = 82)	1.04 ± 1.49	1.0 ± 1.60
Platelet, 109 L⁻¹ (n = 83)	184.2 ± 84.9	177.1 ± 76.9

[*] Baseline vs. EOT, P = 0.03.
[**] Baseline vs. EOT, P = 0.0001. The other comparisons were not significant.
eGFR, estimated glomerular filtration rate; EOT, end-of-treatment; INR, international normalized ratio.

study is to evaluate the efficacy and safety of DAAs for treatment of HCV among patients with mild-to-moderate CKD in a 'real-world' setting. We have evaluated the activity of various combinations of DAAs (such as PrOD or sofosbuvir-based regimens) in a large cohort of patients with stage 1–3 CKD followed at some outpatient clinics all over the world. We found a high viral response (>95%) and this occurred irrespective of viral features, demographic and clinical characteristics. The viral response was great despite our cohort was a difficult group to cure- many patients had advanced liver fibrosis, treatment-experience, and a high rate of co-morbidities (such as arterial hypertension and diabetes); genotypes other than 1 and 4 were frequently found.

Another important point was tolerance to DAAs. This was satisfactory as no drop-outs or hospitalizations occurred; dose reduction or discontinuation of RBV was made in a minority of patients only. Worsening of kidney function was experienced in a few individuals (all having stage 3 CKD at baseline). This fact appears to confirm what has been already observed in the HCV-TARGET database, where patients with eGFR <45 mL/min more frequently experienced worsening of kidney function compared with a control group with eGFR >45 mL/min per 1.73 m².[7] No difference in serum creatinine and eGFR levels at the beginning vs. EOT was observed in the whole population.

From a historical point of view, the purpose of antiviral therapy towards HCV has been to treat and prevent liver-related complications such as cirrhosis, HCV and liver-related death. The World Health Organization 1 has recently proposed the universal treatment of HCV, regardless the liver disease stage, and this recommendation is in keeping with the recent evidence showing that antiviral treatment of HCV prevents the development or deterioration of diabetes, cardiovascular disease, and chronic kidney disease. Survival studies performed in patients with intact kidneys or dialysis population have shown the association between positive anti-HCV serologic status and higher cardiovascular mortality.[15,16] The detrimental role of chronic HCV on the incidence and progression of CKD in the adult general population has been repeatedly emphasized. In addition to the role of HCV in the development of glomerular disease, several biological mechanisms have been advocated to explain the kidney injury in HCV-positive patients; it can be given by endothelial

dysfunction with is promoted by enhanced oxidative stress, pro-inflammatory cytokines, peripheral and hepatic insulin resistance, or non-alcoholic steatohepatitis (NASH).[17–20]

The findings from the current study have some limitations. First, some regimens (such as EBR/GZR or GP) have been administered in a few cases only as these have been recently introduced in the market. The retrospective nature of the current study may have led to incorrect reporting of AEs but we reviewed with accuracy the clinical records of our series and felt that many AEs were associated with the typical comorbidities of these patients. A subgroup of patients was excluded from the safety analysis because the information on AEs was incomplete. The aetiology of CKD was not addressed in our cohort and a few patients had undergone kidney biopsy; this commonly occurs in the 'real-life' clinical practice. Finally, we included patients with CKD identified by calculating eGFR, proteinuria measurements have not been considered for the diagnosis of CKD in our population. This is in analogy with what reported approach in prior studies[8] as quantitative proteinuria assessment is still infrequent in HCV-infected individuals in the 'real-world' activity. Another limitation of the current study is that the post-treatment data are available only over a short follow-up (12 weeks). Studies are in progress in order to evaluate the effects of HCV eradication on the incidence and progression of CKD over longer periods of time.

In summary, various interferon-free combinations of DAAs are currently available for patients with early stage chronic kidney disease. These have given excellent safety and efficacy. What we need now is to accumulate data on the new treatments for HCV able to provide shorter treatment durations, lower pill burden, and no ribavirin use. In addition, studies are under way to assess the link between the eradication of HCV and better renal and cardiovascular survival among patients with CKD.

Abbreviations

AASLD, American Association for the Study of Liver Diseases; AEs, adverse events; AH, arterial hypertension; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CKD-EPI, chronic kidney disease epidemiology collaboration; DAAs, direct-acting antiviral agents; DDIs, drug-drug interactions; DM, diabetes mellitus; EOT, end-of-treatment; eGFR, estimated glomerular filtration rate; gamma-GT, gamma glutamyltranspeptidase; GI, gastrointestinal; HCV, hepatitis C virus; IDSA, Infectious Disease Society of America; INR, international normalized ratio; ITT, intention-to-treat; MDRD, Modification of Diet in Renal Disease; NA, not available; OLT, orthotopic liver transplant; PKD, polycystic kidney disease; SAEs, serious adverse events; SVR, sustained virological response; W12, week 12 (12 weeks after the end of treatment).

Abbreviations (antiviral agents)

DCV, daclatasvir; DSV, dasabuvir; EBR, elbasvir; GP glecaprevir/pibrentasvir; GZR, grazoprevir; SOF, sofosbuvir; IFN, interferon; LDV, ledipasvir; OBV, ombitasvir; pegIFN, pegylated interferon; PrOD, ritonavir-boosted paritaprevir, ombitasvir

and dasabuvir; PTV, paritaprevir; r, ritonavir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; VEL, velpatasvir.

Funding

Conflict of interests

REFERENCES

1. WHO. Hepatitis C. Fact sheet Number 164. http://www.who.int/mediacentre/factsheets/fs164/en/
2. Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int. 2016;36:817–26.
3. Fabrizi F, Donato F, Messa P. Association between hepatitis C virus and chronic kidney disease: a systematic review and meta-analysis. Ann Hepatol. 2018;17:364–91.
4. AASLD (American Association for the Study of Liver Diseases) and IDSA (Infectious Disease Society of America): HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. http://hcvguidelines.org/ [accessed 21.09.17].
5. Aoufi-Rabin S, Garcia-Agudo R, Londoño M, Fraga-Fuentes MD, Barril-Cuadrado G, on behalf on the Spanish Association of the Liver and the Kidney. Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney. J Nephrol. 2018;31:1–13.
6. Ridruejo E, Mendizabal M, Silva M. Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease. Hemodial Int. 2018;22 Suppl. 1:S97–103.
7. Saxena V, Koraishy F, Sise M, Lim J, Schmidt M, Chung R, et al. HCV-TARGET. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807–16.
8. Shih H, Park J, Burman B, Kozarek R, Siddique A. Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. Clin Mol Hepatol. 2017;23:316–22.
9. Sise M, Backman E, Ortiz G, Hundemer GL, Ufere NN, Chute DF, et al. Effect of sofosbuvir based hepatitis C virus therapy on kidney function in patients with CKD. CJASN. 2017;12:1615–23.
10. Levey A, Stevens L, Schmid C, Zhang Y, Castro R, Feldman H, et al., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
11. von Elm, Altman D, Egger M, Pocock S, Gotzsche P, Vanderbroucke J. for the STROBE initiative: the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495–9.
12. Roth D, Nelson D, Bruchfeld A, Liapakis A, Silva M, Monsiur H, et al. Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (The C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537–45.
13. Pockros P, Reddy R, Mantry P, Cohen E, Bennett M, Sulkowski M, et al. Efficacy and direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590–8.
14. Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448–55.
15. Petta S, Maida M, Macaluso F, Barbara M, Licata A, Craxì A, et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology. 2016;150:145–55.
16. Fabrizi F, Dixit V, Messa P. Hepatitis C virus and mortality among patients on dialysis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2019 [in press].
17. Wong R, Gish R. Metabolic manifestations and complications associated with chronic hepatitis C virus infection. Gastroenterol Hepatol (NY). 2016;12:293–9.
18. Dong T, Aby E, Benhammou J, Kawamoto J, Han S, May F, et al. Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves haemoglobin A1c. World J Hepatol. 2018;10:612–21.
19. Desbois A, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review. World J Gastroenterol. 2017;23:1697–711.
20. Schmidt F, Zimmermann T, Wenz T, Schnorbus B, Ostad M, Feist C, et al. Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improve vascular endothelial function. Int J Cardiol. 2018;271:296–300.